title: Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
abstract: Cancer treatment-induced bone loss (CTIBL) is one of the most important side effects of adjuvant antineoplastic treatment in hormone-dependent neoplasms. Chemotherapy, GnRH analogs and tamoxifen can induce marked bone loss in premenopausal women with early breast cancer. Aromatase inhibitors (AIs) are replacing tamoxifen as the preferred treatment for postmenopausal women. As a class effect, steroidal (exemestane) and non-steroidal (anastrozole and letrozole) AIs increase bone turnover and cause bone loss (4%-5% over 2 years). When compared to tamoxifen, the risk of getting a clinical fracture under AI treatment is increased by 35%-50%. In patients with prostate cancer, androgen deprivation therapy (ADT) increases bone turnover, reduces bone mass (4%-5% per year) and increases the fracture rate depending on the duration of therapy. Zoledronic acid can prevent accelerated bone loss induced by goserelin in premenopausal women, by letrozole in postmenopausal women and by ADT in men. More limited data indicate that weekly alendronate or risedronate could also be effective for preventing CTIBL. Initiation of therapy early, prior to the occurrence of severe osteoporosis, rather than after, may be more effective. Bisphosphonate treatment should be considered in osteoporotic but also in osteopenic patients if other risk factor(s) for fractures are present.
authors: Department of Medicine, CHU Brugmann and Institute J Bordet, Université Libre de Bruxelles, 4 place van Gehuchten, Brussels 1020, Belgium. jean-jacquess.body@chu-brugmann.be
authors: J J
authors: JJ
authors: Body
authors: P
authors: P
authors: Bergmann
authors: S
authors: S
authors: Boonen
authors: Y
authors: Y
authors: Boutsen
authors: J P
authors: JP
authors: Devogelaer
authors: S
authors: S
authors: Goemaere
authors: J Y
authors: JY
authors: Reginster
authors: S
authors: S
authors: Rozenberg
authors: J M
authors: JM
authors: Kaufman
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy*; D017698:Postmenopause; D017697:Premenopause; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents
references: Lancet. 2002 Sep 14;360(9336):817-24
references: 12243915
references: J Clin Oncol. 2002 Dec 15;20(24):4628-35
references: 12488406
references: J Clin Oncol. 1997 Mar;15(3):955-62
references: 9060533
references: J Clin Oncol. 1996 Jan;14 (1):78-84
references: 8558225
references: Ann Oncol. 2003 Sep;14 (9):1399-405
references: 12954579
references: J Urol. 2006 Dec;176(6 Pt 2):S50-4
references: 17084167
references: J Clin Oncol. 2007 Mar 20;25(9):1038-42
references: 17369566
references: N Engl J Med. 2007 May 3;356(18):1809-22
references: 17476007
references: J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
references: 16288118
references: J Urol. 2000 Jan;163(1):181-6
references: 10604342
references: J Bone Miner Res. 2000 Jun;15(6):993-1000
references: 10841167
references: J Clin Oncol. 2007 Mar 1;25(7):820-8
references: 17159195
references: N Engl J Med. 1998 Aug 27;339(9):599-603
references: 9718379
references: Lancet. 2005 Aug 6-12;366(9484):455-62
references: 16084253
references: J Urol. 1999 Apr;161(4):1219-22
references: 10081873
references: Br J Cancer. 1990 Feb;61(2):308-10
references: 2310683
references: Cancer. 2004 Mar 1;100(5):892-9
references: 14983482
references: J Clin Oncol. 2006 Nov 20;24(33):5305-12
references: 17114665
references: J Clin Oncol. 2002 Aug 1;20(15):3317-27
references: 12149306
references: Osteoporos Int. 2003 Dec;14(12):1001-6
references: 14530912
references: N Engl J Med. 1998 Mar 12;338(11):736-46
references: 9494151
references: Bone. 2002 Jul;31(1):32-6
references: 12110409
references: Clin Cancer Res. 1998 Mar;4(3):527-34
references: 9533518
references: Semin Oncol. 2001 Aug;28(4 Suppl 11):49-53
references: 11544576
references: Clin Breast Cancer. 2006 Jun;7(2):127-32
references: 16800971
references: J Clin Oncol. 2000 Apr;18(7):1570-93
references: 10735906
references: J Urol. 1997 Feb;157(2):439-44
references: 8996327
references: J Urol. 2006 Jan;175(1):136-9; discussion 139
references: 16406890
references: Eur J Cancer. 2006 May;42(8):1044-51
references: 16554149
references: Oncology (Williston Park). 2005 Apr;19(5):651-8
references: 15945345
references: J Bone Miner Res. 2006 Aug;21(8):1215-23
references: 16869719
references: J Clin Oncol. 2005 Jan 20;23(3):619-29
references: 15545664
references: J Clin Endocrinol Metab. 2000 Jan;85(1):219-23
references: 10634390
references: Eur J Cancer. 2006 Nov;42(17 ):2968-75
references: 16963261
references: J Surg Oncol. 1997 Feb;64(2):167-72
references: 9047258
references: J Clin Endocrinol Metab. 2004 Aug;89(8):3841-6
references: 15292315
references: J Clin Densitom. 2006 Oct-Dec;9(4):431-7
references: 17097529
references: J Urol. 2001 Nov;166(5):1724-8
references: 11586210
references: Osteoporos Int. 2005 Jun;16(6):581-9
references: 15616758
references: N Engl J Med. 2001 Sep 27;345(13):948-55
references: 11575286
references: Ann Intern Med. 2006 May 16;144(10):753-61
references: 16702591
references: Support Care Cancer. 2006 May;14(5):408-18
references: 16450087
references: J Clin Endocrinol Metab. 2003 Jul;88(7):3075-81
references: 12843146
references: Cancer. 2003 Nov 1;98(9):1802-10
references: 14584060
references: J Urol. 2003 Jun;169(6):2008-12
references: 12771706
references: Oncology (Williston Park). 1998 Apr;12(4):499-505; discussion 506-8
references: 9575524
references: Clin Endocrinol (Oxf). 1994 Oct;41(4):525-30
references: 7525125
references: Lancet. 2005 Jan 1-7;365(9453):60-2
references: 15639680
references: J Clin Oncol. 2004 Jul 1;22(13):2546-53
references: 15226323
references: Oncologist. 2006 Nov-Dec;11(10):1121-31
references: 17110632
references: J Clin Oncol. 2005 Aug 1;23 (22):5126-37
references: 15983390
references: J Clin Endocrinol Metab. 2002 Nov;87(11):4907-13
references: 12414849
references: J Clin Oncol. 1997 Apr;15(4):1341-7
references: 9193325
references: J Clin Densitom. 2004 Spring;7(1):37-44
references: 14742886
references: J Clin Oncol. 2005 Dec 1;23(34):8580-7
references: 16314620
references: Hematol Oncol Clin North Am. 1996 Jun;10(3):727-47
references: 8773508
references: N Engl J Med. 2005 Dec 29;353(26):2747-57
references: 16382061
references: Am J Med. 1997 Aug 18;103(2A):12S-17S; discussion 17S-19S
references: 9302893
references: J Clin Oncol. 2001 Jul 15;19(14):3306-11
references: 11454877
references: J Bone Miner Res. 2002 Jan;17(1):172-8
references: 11771665
references: N Engl J Med. 2005 Jan 13;352(2):154-64
references: 15647578
references: N Engl J Med. 1992 Mar 26;326(13):852-6
references: 1542321
references: J Clin Endocrinol Metab. 1999 Oct;84(10):3431-4
references: 10522975
references: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
references: 9747868
references: Expert Opin Pharmacother. 2003 Apr;4(4):567-80
references: 12667119
references: J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
references: 11836291
references: Cancer. 1997 Feb 1;79(3):545-50
references: 9028366
references: Cancer. 2001 Sep 15;92(6):1444-50
references: 11745221
references: Clin Cancer Res. 2004 Sep 1;10 (17 ):5717-23
references: 15355898
references: Am J Clin Oncol. 2003 Aug;26(4):S27-33
references: 12902874
references: N Engl J Med. 2003 Jun 12;348(24):2431-42
references: 12802030
references: J Clin Oncol. 2007 Mar 1;25(7):829-36
references: 17159193
references: J Clin Oncol. 2003 Nov 1;21(21):4042-57
references: 12963702
references: N Engl J Med. 2003 Nov 6;349(19):1793-802
references: 14551341
references: N Engl J Med. 2003 Oct 23;349(17):1676-9; discussion 1676-9
references: 14573746
references: Calcif Tissue Int. 1995 Aug;57(2):97-9
references: 7584882
references: N Engl J Med. 2006 Nov 30;355(22):2278-81
references: 17135582
references: J Clin Oncol. 2006 Aug 1;24(22):3629-35
references: 16822845
references: Urol Clin North Am. 2004 May;31(2):331-52
references: 15123412
references: N Engl J Med. 2004 Mar 11;350(11):1081-92
references: 15014181